TrialPath
Recruiting

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

NCT07621809 · Novartis
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Randomized, Double-blind, Placebo-controlled, 2-arm Multicenter Phase III Study to Assess the Efficacy and Safety of Ianalumab in Participants With Sjogren's Disease With High Symptom Burden (THALASSA)
About this study
This is a double-blind, randomized, placebo-controlled multicenter 2-arm Phase III study, evaluating 300 mg ianalumab s.c. against placebo s.c. in adult participants with Sjögren's disease with high symptom burden.
Eligibility criteria
Inclusion Criteria: * Male or female participants ≥ 18 years of age or as per country-specific legal adult age, whichever is higher * Classification of Sjögren's disease according to ACR/EULAR 2016 criteria. * Seropositive for anti-Ro/SSA antibodies at screening * SSSD oral dryness score ≥ 5 and overall SSSD summary score ≥5 collected over 14 consecutive days during the Screening 2 period * Screening ESSDAI biologic and/or hematologic domain \> 0 Note: laboratory abnormalities for scoring must be confirmed as associated with Sjögren's disease and not be due to other underlying conditions. * Stimulated whole salivary flow (sSF) rate \> 0.3 mL/min at screening * Participants taking hydroxychloroquine (≤ 400 mg/day) are allowed to continue their medication, and must have been on a stable dose for at least 4 weeks prior to screening, which should be maintained throughout the 52 weeks of the blinded treatment period. * Predniso(lo)ne ≤ 5 mg/day or equivalent are allowed for up to 16 weeks post-randomization. Exclusion Criteria: * Presence of another autoimmune rheumatic disease that is active and constitutes the principal illness, specifically: * Systemic sclerosis (SSc) * Any other associated connective tissue disease (e.g., lupus nephritis (LN), large vessel vasculitis (LVV), Sharp syndrome (mixed connective tissue disease)) that is active and requires immunosuppressive treatment outside the scope of this trial and would impede on Sjögren's disease organ domain assessments. * Concurrent diagnosis or history of fibromyalgia or overlapping inflammatory diseases * Prior treatment with B-cell-depleting therapy (e.g., rituximab, other anti-CD20 mAb, anti-CD22 mAb, or anti-CD52 mAb) within: * 36 weeks prior to randomization, or * As long as B-cell count is less than the lower limit of normal (LLN) or baseline value prior to receipt of previous B-cell-depleting therapy (whichever is lower) at Screening. * Prior treatment with ianalumab * Prior treatment with any of the following within the given period prior to Screening: * Within 5 half-lives prior to Screening: iscalimab (anti-CD 40 mAb), belimumab (anti-BAFF mAb), abatacept (CTLA4-Fc Ig), anti-tumor necrosis factor alpha (TNFα) biologic agents, immunoglobulins (i.v./s.c.), plasmapheresis, any other investigational biologic medicines under investigation for Sjögren's disease * Within 4 weeks OR drug-specific 5 half-lives elimination period (if longer than 4 weeks) prior to screening: i.v. or oral cyclophosphamide, mycophenolate mofetil (MMF), methotrexate, azathioprine, i.v. or oral cyclosporine A or any other immunosuppressants (e.g., JAK inhibitors or other kinase inhibitors). * History of hypersensitivity to any of the study drugs or their excipients, or to drugs of similar chemical classes (e.g., mAb of IgG1 class) or to any of the constituents of the study drug formulation (sucrose, L-histidine hydrochloride/L-histidine, polysorbate 20).
Study design
Enrollment target: 570 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2026-07-16
Estimated completion: 2033-08-14
Last updated: 2026-11-09
Interventions
Drug: VAY736Drug: Placebo
Primary outcomes
  • • Change from baseline in SSSD oral dryness score (Baseline to Week 52)
Sponsor
Novartis Pharmaceuticals · industry
Contacts & investigators
ContactNovartis Pharmaceuticals · contact · novartis.email@novartis.com · 1-888-669-6682
ContactNovartis Pharmaceuticals · contact · +41613241111
All locations (72)
Sun Valley Arthritis Center LtdRecruiting
Peoria, Arizona, United States
Unity Health RheumatologyRecruiting
Searcy, Arkansas, United States
Medvin Clinical ResearchRecruiting
Van Nuys, California, United States
Clinical Res Of W FloridaRecruiting
Clearwater, Florida, United States
GNP ResearchRecruiting
Cooper City, Florida, United States
Clinical Research of West Florida IncRecruiting
Tampa, Florida, United States
Willow Rheumatology WellnessRecruiting
Willowbrook, Illinois, United States
Tufts Medical CenterRecruiting
Boston, Massachusetts, United States
Clinical Research Inst of MIRecruiting
Saint Clair Shores, Michigan, United States
Arthritis Rheumatology and Bone Disease Associates PARecruiting
Voorhees Township, New Jersey, United States
St Lawrence Health SystemRecruiting
Potsdam, New York, United States
On Site Clinical Solutions LlcRecruiting
Charlotte, North Carolina, United States
Carolina Arthritis AssociatesRecruiting
Wilmington, North Carolina, United States
RAO Research LLCRecruiting
Oklahoma City, Oklahoma, United States
West Tennessee Research InstituteRecruiting
Jackson, Tennessee, United States
Shelby Research LLCRecruiting
Memphis, Tennessee, United States
Novel Research LLCRecruiting
Bellaire, Texas, United States
Arthritis Care of TexasRecruiting
Corpus Christi, Texas, United States
Precision Comprehensive Clinical Research SolutionsRecruiting
Euless, Texas, United States
Abigail Neiman MD PARecruiting
Houston, Texas, United States
Accurate Clinical ResearchRecruiting
League City, Texas, United States
TEKTONRecruiting
Leander, Texas, United States
Arthritis Northwest PLLCRecruiting
Spokane, Washington, United States
Novartis Investigative SiteRecruiting
Maroochydore, Queensland, Australia
Novartis Investigative SiteRecruiting
Graz, Austria
Novartis Investigative SiteRecruiting
São Paulo, São Paulo, Brazil
Novartis Investigative SiteRecruiting
Sydney, Nova Scotia, Canada
Novartis Investigative SiteRecruiting
Rimouski, Quebec, Canada
Novartis Investigative SiteRecruiting
Sherbrooke, Quebec, Canada
Novartis Investigative SiteRecruiting
Shenzhen, Guangdong, China
Novartis Investigative SiteRecruiting
Nanjing, Jiangsu, China
Novartis Investigative SiteRecruiting
Taiyuan, Shanxi, China
Novartis Investigative SiteRecruiting
Chengdu, Sichuan, China
Novartis Investigative SiteRecruiting
Wenzhou, Zhejiang, China
Novartis Investigative SiteRecruiting
Ningbo, Zhengjiang, China
Novartis Investigative SiteRecruiting
Beijing, China
Novartis Investigative SiteRecruiting
Beijing, China
Novartis Investigative SiteRecruiting
Beijing, China
Novartis Investigative SiteRecruiting
Jiujiang, China
Novartis Investigative SiteRecruiting
Bogota, Cundinamarca, Colombia
Novartis Investigative SiteRecruiting
Bogotá, Colombia
Novartis Investigative SiteRecruiting
Brno, Czechia
Novartis Investigative SiteRecruiting
Dijon, France
Novartis Investigative SiteRecruiting
La Roche-sur-Yon, France
Novartis Investigative SiteRecruiting
Le Kremlin-Bicêtre, France
Novartis Investigative SiteRecruiting
Le Mans, France
Novartis Investigative SiteRecruiting
Lille, France
Novartis Investigative SiteRecruiting
Montpellier, France
Novartis Investigative SiteRecruiting
Paris, France
Novartis Investigative SiteRecruiting
Saint-Priest-en-Jarez, France
Novartis Investigative SiteRecruiting
Erlangen, Germany
Novartis Investigative SiteRecruiting
Budapest, Hungary
Novartis Investigative SiteRecruiting
Kochi, Kerala, India
Novartis Investigative SiteRecruiting
Nashik, Maharashtra, India
Novartis Investigative SiteRecruiting
Jaipur, Rajasthan, India
Novartis Investigative SiteRecruiting
Belagavi, India
Novartis Investigative SiteRecruiting
Leeuwarden, Provincie Friesland, Netherlands
Novartis Investigative SiteRecruiting
Groningen, Provincie Groningen, Netherlands
Novartis Investigative SiteRecruiting
Rotterdam, South Holland, Netherlands
Novartis Investigative SiteRecruiting
Braga, Portugal
Novartis Investigative SiteRecruiting
Košice, Slovakia
Novartis Investigative SiteRecruiting
Poprad, Slovakia
Novartis Investigative SiteRecruiting
Bundang Gu, Gyeonggi-do, South Korea
Novartis Investigative SiteRecruiting
Suwon, Gyeonggi-do, South Korea
Novartis Investigative SiteRecruiting
Gwangju, South Korea
Novartis Investigative SiteRecruiting
Seoul, South Korea
Novartis Investigative SiteRecruiting
Santander, Cantabria, Spain
Novartis Investigative SiteRecruiting
Madrid, Spain
Novartis Investigative SiteRecruiting
Seville, Spain
Novartis Investigative SiteRecruiting
Bern, Switzerland
Novartis Investigative SiteRecruiting
Hsinchu, Taiwan
Novartis Investigative SiteRecruiting
Swindon, United Kingdom
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden · TrialPath